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Abstract
Aims/hypothesis To overcome the donor shortage in the
treatment of advanced type 1 diabetes by islet transplanta-
tion, human embryonic stem cells (hESCs) show great po-
tential as an unlimited alternative source of beta cells.
hESCs may have immune privileged properties and it is
important to determine whether these properties are pre-
served in hESC-derived cells.
Methods We comprehensively investigated interactions of
both innate and adaptive auto- and allo-immunity with
hESC-derived pancreatic progenitor cells and hESC-derived
endocrine cells, retrieved after in-vivo differentiation in cap-
sules in the subcutis of mice.
Results We found that hESC-derived pancreatic endoder-
mal cells expressed relatively low levels of HLA endorsing
protection from specific immune responses. HLA was up-
regulated when exposed to IFNγ, making these endocrine
progenitor cells vulnerable to cytotoxic T cells and
alloreactive antibodies. In vivo-differentiated endocrine
cells were protected from complement, but expressed more
HLA and were targets for alloreactive antibody-dependent
cellular cytotoxicity and alloreactive cytotoxic T cells. After
HLA compatibility was provided by transduction with HLA-
A2, preproinsulin-specific T cells killed insulin-producing
cells.
Conclusions/interpretation hESC-derived pancreatic progen-
itors are hypoimmunogenic, while in vivo-differentiated en-
docrine cells represent mature targets for adaptive immune
responses. Our data support the need for immune intervention
in transplantation of hESC-derived pancreatic progenitors.
Cell-impermeable macro-encapsulation may suffice.
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MCP Membrane cofactor protein
MIP Membrane attack complex-inhibitory protein
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Introduction
Beta cell replacement by islet transplantation can functionally
cure long-standing type 1 diabetes but its implementation is
limited by the lack of donor organs, loss of graft function over
time and the side effects of obligatory immunosuppression.
Alternative sources of beta cells could overcome the shortage
of human islets, while novel protective strategies and/or the
potential for immune privilege of an alternative source of beta
cells may help to overcome the immunosuppressive burden.
Several alternative sources of beta cells are currently being
explored, including human embryonic stem cells (hESCs) [1],
proliferating beta cell lines [2], induced pluripotent stem cells
[3, 4] and xenogeneic islets [5, 6]. hESC-derived beta cells are
well on the way to clinical translation with recent publications
on improved safety and scaling of a protocol being made by
Kroon and colleagues [1, 7, 8].
After transplantation, hESC-derived beta cells face the
challenges posed by the human immune system for the first
time. Partial early loss of grafts through innate immune reac-
tions may be overcome by transplanting more cells or by
choosing an alternative site to the liver. However, both recur-
rent autoimmunity and alloreactive responses remain a persis-
tent threat to transplanted human-derived beta cells despite
immunosuppression [9–11]. Additionally, alloreactive re-
sponses provoked by a graft can be a risk for future transplan-
tations [12–14]. Conversely, complete lack of immune inter-
action can leave cells vulnerable to infections or may invoke
an innate immune attack by natural killer (NK) cells [15]. We
recently showed this for immortalised beta cell lines [16].
Embryonic stem cells have immune privileged properties
and can resist alloreactive responses [17]. However, differen-
tiation of hESCs to other cell types can result in the loss of this
immunological privilege [17–21]. Insights into the immuno-
genicity of the alternative sources of beta cells can help to
guide the choice of immune-protective strategies and the rel-
evant immune monitoring to be employed in clinical introduc-
tion. We therefore investigated the immunogenicity of hESC-
derived beta cells and their progenitors to adaptive immune
responses relevant in transplantation.
Methods
Biological reagents hESC-derived pancreatic endodermal
cells (hESC-PEs) were prepared from the CyT49 cell line
(HLA A1, A3, B44, B57) at ViaCyte (San Diego, CA,
USA), cryopreserved and shipped to Brussels, as described
[22]. For each series of experiments, cells were thawed and
cultured for 72 h in db-N50-K50-E50 medium [7]. A fraction
of the cells was sent to Leiden in db medium [1] and the remain-
ing cells were transplanted in Brussels. Encapsulated grafts were
prepared by loading 4×106 cells in a macro-device (ViaCyte)
and were implanted in the subcutis of non-diabetic NOD/severe
combined immunodeficiency (SCID) male mice (7–8 weeks
old, NOD.CB17-Prkdcscid/J; Charles River, L’Arbresle,
France). Implants were analysed in vivo and ex vivo as
described [22]. In vivo graft function was followed over
20 weeks through measuring plasma human C-peptide levels
15 min after intraperitoneal injection of glucose; at post-
transplant week 20, all recipientswere confirmed to have reached
plasma human C-peptide levels above 1 ng/ml. Implants were
resected at post-transplant week 20–25 and dispersed for analysis
before sending to Leiden in phosphate-buffered Ham’s F-10
medium (Gibco, Bleiswijk, the Netherlands), supplemented with
0.5% human albumin, 2 mmol/l L-leucine and 2 mmol/l
L-glutamine. Upon arrival, hESC-PEs and in vivo-differentiated
cells were dissociated with 0.05% trypsin-EDTA 1X (Gibco) to
single cells for immunological assays.
Human peripheral blood mononuclear cells (PBMCs) were
separated from whole blood (for T cells) or buffy coats (for
lymphocytes) by Ficoll–Hypaque density gradient. Peripheral
blood lymphocytes were left over after CD14 depletion from
PBMCs with CD14-MicroBeads according to the manufac-
turer’s protocol (Miltenyi Biotec, Auburn, CA, USA).
Preproinsulin (PPI)-specific T cell clone 1E6 generation was
described previously [23]. Briefly, PBMCs from an individual
with type 1 diabetes were stimulated with PPI15-24 peptide.
PPI-specific cytotoxic T lymphocytes (CTLs) were sorted by
FACS and expanded. Alloreactive CTL clones JS132 (to
HLA-A2) and C776 (to HLA-A1) were generated by stimu-
lating PBMCs, collected from a healthy donor, with irradiated
Epstein–Barr virus (EBV)-transformed B cell line expressing
the HLA of interest. After several rounds of stimulation and
enrichment, the alloreactive populationwas cloned by limiting
dilution at 0.5 cell/well [24]. CTL clones to cytomegalovirus
(CMV) peptides VTEHDTLLY in HLA-A1 (clone 3c8) and
NLVPMVATV in HLA-A2 (clone 18) were generated by sin-
gle cell sorting of CD8+ T cells stained with the respective
tetramers and expanded using phytohaemagglutinin stimula-
tion [25]. HEK-293 and primary tubular epithelial cells
(PTECs, line HK-2) were cultured in DMEM/F-12 medium
(Invitrogen, Landsmeer, the Netherlands) supplemented with
2 mmol/l L-glutamine, 25 mmol/l HEPES, 50 U/ml penicillin
and 50 μg/ml streptomycin (all purchased from Invitrogen)
and, for PTECs, also 5 μg/ml insulin, 5 μg/ml transferrin,
5 ng/ml selenium, 36 ng/ml hydrocortisone and 10 ng/ml epi-
dermal growth factor (all purchased from Sigma, Zwijndrecht,
the Netherlands). B lymphocytes (B-LCL) lines were cultured
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in IMDM (Invitrogen) supplemented with 2 mmol/l
L-glutamine, 25 mmol/l HEPES, 50 U/ml penicillin,
50 μg/ml streptomycin and 5% FBS.
Human monoclonal antibodies recognising HLA-A68 or
HLA-B8 were selected from a panel as described previously
[26]. In short, heterohybridomas were created by EBV trans-
formation and cloning of B-LCL of multiparous women. The
HLA specificities of the produced human monoclonal anti-
bodies were validated using a complement-dependent cyto-
toxicity test on PBMCs.
Beta cell-specific T helper (Th) cell supernatant fractions
were generated by incubating islet preparation reactive Th1
clone (1c6) from a diabetic patient with HLA-matched
PBMCs pre-incubated with or without 10 μg/ml antigen in
RPMI 1640 medium (Gibco) mixed without and with
11 mmol/l glucose to achieve 5.6 mmol/l D-glucose and sup-
plemented with 2 mmol/l glutamine (Gibco) [27]. After 3 days
the supernatant fraction was harvested and frozen until use.
For compatibility with autoreactive CTL clone 1E6,
beta cell line EndoC-βH1 was transduced with a lentiviral
vector containing HLA-A02:01 under elongation factor
1α (EF1α) promotor at multiplicity of infection of 2.
Third-generation self-inactivating lentivirus vectors were
produced as described previously [28]. The generation of
human cell lines and antibodies was carried out after
obtaining informed consent and with approval of the in-
stitutional review board, in accordance with the 2008 re-
vised principles of the Declaration of Helsinki.
Alloreactivity assays Alloreactive cellular cytotoxicity was
assessed by chromium release (PerkinElmer, Waltham, MA,
USA). Briefly, dispersed hESC-derived cells were labelled
with 51Cr for 60 min, washed three times and incubated with
alloreactive T cells or, for antibody-dependent cellular cyto-
toxicity (ADCC), human monoclonal antibodies and periph-
eral blood lymphocytes in different effector-to-target ratios for
4–6 h or overnight. 51Cr release in supernatant fractions was
assessed on a WIZARD2 γ-counter (Perkin Elmer, Waltham,
MA, USA). Specific lysis was calculated as [(experimental
release− spontaneous release) / (max release − spontaneous
release)] × 100%.
Complement-dependent cytotoxicity was assessed with
hESC-derived cells as targets in a clinical cross match assay
[29]. In short, dispersed cells were incubated with serum con-
taining alloreactive antibodies with known specificity and in-
cubated in triplicate in Therasaki plates at room temperature
for 1 h. Rabbit complement (Inno-train, Frankfurt am Main,
Germany) was added and the plates were incubated for anoth-
er hour. Cell lysis was assessed by adding propidium iodide–
ink solution and measured on the Patimed system (Leica,
Rijswijk, the Netherlands). Minimal and maximum lysis was
set to HLA-antibody-negative serum cell death and parallel
lysis of HLA-matched lymphocyte targets, respectively.
Autoreactive assays At 20 h post transduction, virus super-
natant fraction was removed from HLA-A02:01 transduced
cells by centrifugation. The cells were cultured in Ham’s F-10
medium (Gibco) supplemented with 200 mmol/l glutamine
(Gibco), 0.5% BSA fraction V (Sigma-Aldrich, Zwijndrecht,
the Netherlands), 1 mol/l CaCl2 and 1.8 g/l D-glucose for 4 days
to allow transgene expression before trypsin dispersion and in-
cubation with PPI-specific CTL clone 1E6 or CMV-specific
clone 18 in a 1:5 ratio. After overnight incubation, cells were
stained with Fixable Viability Dye eFluor 450 (eBioscience,
Vienna, Austria), CD45-PerCP (2D1; BD, Breda, the
Netherlands) and HLA-A2–fluorescein isothiocyanate (FITC)
(BD), then fixed in paraformaldehyde and permeabilised with
saponin before staining with guinea pig anti-insulin (Free
University Brussels, Brussels, Belgium) and donkey anti-
guinea pig Alexa 647 (Jackson Immunoresearch Laboratories,
West Grove, PA, USA). Cells were measured on a CANTO II
flow cytometer (BD). Transduction efficiency was determined
by staining with anti-HLA-A2–Allophycocyanin (APC)
(Bb7.2; BD) on a Calibur flow cytometer (BD).
Cell surface staining Cell surface antigens were analysed by
FACS on a BD FACSCalibur after 20min staining at 4°Cwith
antibodies to HLA class I–FITC (W6/32; BD), HLA-DR–
FITC (L243; BD), IgG1–APC (MOPC-21; BD), IgG2a–
FITC (G155-178; BD), IgG2a–Phycoerythrin (G155-178;
BD), ant i-CD46–APC (MEM-258; ImmunoTools,
Friesoythe, Germany), anti-CD55–Phycoerythrin (IA10;
BD) and anti-CD59–APC (OV9A2, eBioscience).
Experimental conditions
Data were excluded if positive or negative controls failed.
Additional intermediate titrations were performed in par-
allel in most samples that were left out for clarity to the
reader. These data supported the conclusion. Cell lines for
comparison were available in our laboratory unless stated
otherwise and mycoplasma contamination was regularly
excluded. Non-commercial antibodies had been generated
and validated in our department before [26] and were of
IgG subclass.
Statistical analysis Data are represented as mean and SE un-
less stated otherwise. GraphPad Prism 6.0 (GraphPad
Software, La Jolla, CA, USA) was used to create graphs and
perform analysis. Student’s t test was used to compare contin-
uous data and Fisher’s exact test was used for binominal data;
p<0.05 was considered statistically significant. All immune
assays were replicated three times.
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Results
Cell composition and function was assessed in hESC-PEs and
cells retrieved from implants (hESC-derived endocrine cells
[hESC-ECs]). These results and comparison with human islets
have been reported [22]. Here, expression of HLAwas assessed
on the cell surface of hESC-PEs and hESC-ECs. This expres-
sion is essential for autoreactive, virus-specific T cell and
alloreactive immune responses. hESC-PEs expressed very low
levels of HLA class I, although HLA class I could be upregu-
lated to reach levels expressed by other cell lines after exposure
to the inflammatory cytokine, IFNγ (Fig. 1a). On the other hand,
the hESC-ECs expressed normal levels of HLA class I, which
were only slightly upregulated by IFNγ. HLA class II is gener-
ally not expressed on endocrine cells. In line with this only
minimal expression over isotype control was noted for hESC-
ECs on 3.5% of cells (and on 7.7% of cells after upregulation
with IFNγ). Also, expression of complement receptors, which
protect cells from complement-mediated destruction, was
assessed. Both hESC-PEs and hESC-ECs expressed membrane
cofactor protein (MCP; CD46) at the level of other cell lines
(Fig. 1b), together with high levels of membrane attack
complex-inhibitory protein (MIP; CD59) (Fig. 1d). The differ-
entiated hESC-ECs clearly expressed decay-accelerating factor
Fig. 1 Expression of HLA and complement receptors. FACS analysis of
HLA class I (a) and complement inhibitory receptors CD46 (MCP) (b),
CD55 (DAF) (c) and CD59 (MIP) (d) expression on trypsin-dissociated
hESC-PEs and differentiated hESC-ECs, compared with EBV-immortalised
B-LCL, PTECs and HEK293 cells. HLA class I was upregulated by IFNγ
(1000 IU/ml; dashed line). Light traces represent isotype control staining
Fig. 2 Alloreactive and virus-specific CTLs can target hESC-PEs and
differentiated hESC-ECs. ESC-PEs (a, b, d, e, g, h, j, k) and hESC-ECs
(c, f, i, l) expressing HLA-A1 were labelled with 51Cr and incubated with
alloreactive CTLs targeting HLA-A1 (black circles, solid line) or targeting
third party HLA-A2 (white circles, dashed line) (a–f) and virus-specific
CTLs recognising CMV peptide in HLA-A1 on peptide-pulsed cells
(black circles, solid line) or without peptide (white circles, dashed line)
(g–l). Specific lysis after 4 h (a–c, g–i) and 20 h (d–f, j–l) was calculated
relative to spontaneous lysis without Tcells and chemically -induced max-
imum lysis. Inflammation was mimicked (b, e, h, k) by pre-incubation
with IFNγ (1000 IU/ml), which upregulated HLA expression. Statistical
results are available in ESM Fig. 1
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Fig. 4 Alloreactive antibodies induce cellular cytotoxicity but differentiated
hESC-ECs resist complement-dependent cytotoxicity. (a–c) hESC-PEs (a,
b) and differentiated hESC-ECs (c) were labelled with 51Cr and incubated
with specific (black circles, solid line) and non-specific (white circles, dashed
line) alloreactive antibodies and peripheral blood lymphocytes for 6 h.
Chromium release was measured and specific lysis was calculated relative
to spontaneous lysis without T cells and chemical induced maximum lysis.
Inflammation was mimicked by pre-incubation with IFNγ (1000 IU/ml),
upregulating HLA expression (b). (d, e) hESC-PEs (d) and hESC-ECs (e)
were incubated with serum containing HLA specific antibodies to A1 and
B44 for 1 h and then for 1 h with rabbit complement. Lysis was assessed by
propidium iodide staining with automated microscopy measurement and
specific lysis calculated relative to cell death without specific antibodies
and parallel specific lysis of lymphocyte controls. Inflammation was mim-
icked by pre-incubation with IFNγ (1000 IU/ml), upregulating HLA expres-
sion (black bars); white bars, no pre-incubation with IFNγ. hESC-ECs were
only tested after IFNγ pre-incubation. Statistical results are available in ESM
Fig. 2
Fig. 3 PPI-specific CTLs recognise and kill hESC-derived beta cells. (a)
hESC-ECs were transduced with HLA-A2 for compatibility with
autoreactive CTL clone 1E6. FACS analysis of HLA-A2 expression showed
expression on >50% of hESC-ECs (dark grey; isotype control in light grey).
(b) After 4 days’ upregulation of the transgene, hESC-derived cells were
incubated with autoreactive CTL clone 1E6 recognising PPI peptide in
HLA-A2 or clone 18 recognising an irrelevant CMV peptide for 20 h.
Specific cytotoxicity was assessed by FACS by gating insulin-positive,
CD45-negative, single cells. (c, d) Gated beta cell-like cells expressing
HLA-A2 (red) were killed overnight with >90% efficiency by PPI-specific
CTLs (c) compared with non-specific CTLs recognising CMV peptide (d).
(e) The killing efficiency may be at maximum since this could not be in-
creased by pulsing the beta cell-like cells with PPI peptide before exposure to
PPI-specific CTLs. FSC-A, forward scatter: area; FSC-W, forward scatter:
width; SSC-A, side scatter: area
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(DAF; CD55), similar to PTEC line HK-2 and HEK293 cells,
while this expression was lower on hESC-PEs (Fig. 1c).
Next, hESC-derived cells were tested for resistance or sensi-
tivity to cytotoxic T cells. The hESC-PE was resistant to
alloreactive CTLs directed against the specific HLA expressed
by the nESC-PE in a 4 h chromium release assay (p>0.05), but
became vulnerable to the CTLs after exposure to IFNγ, which
had upregulated HLA (p=0.0005; Fig. 2).
To test recognition by memory autoreactive CTLs, HLA
matching had to be introduced. Beta cell-specific autoreactive
memory CTLs of type 1 diabetes patients pose a particular
threat to transplanted beta cells if transplanted beta cells match
recipient HLA. HLA-A2 was lentivirally introduced in hESC-
ECs under the constitutive EF1α promoter (55% transduction
efficiency). It was thus found that hESC-ECs expressing in-
sulin and HLA-A2 were specifically killed by PPI-specific
CTLs with > 90% efficiency when compared with non-
specific CTLs (p<0.0001; Fig. 3). The viability of mock-
transduced insulin-expressing hESC-ECs incubated with PPI
CTLs was comparable with that of transduced cells incubated
with non-specific CTLs (73.2 and 71.5%, respectively).
Adding PPI-positive control peptide did not further increase
killing of insulin-expressing cells, but did lead to recognition
and killing of HLA-A2 transduced cells that did not express
insulin (data not shown).
To confirm peptide-specific killing of hESC-derived cells
through their cognate HLA, we assessed killing by CTLs
recognising CMV peptide in cognate HLA-A1. Similar to
alloreactive CTLs, CMV-specific CTLs did not effectively kill
hESC-PEs loaded with CMV peptide unless the hESC-PEs
were exposed to IFNγ or the assay was prolonged. The dif-
ferentiated hESC-ECs were vulnerable to alloreactive and
CMV-specific CTLs without prior IFNγ treatment, while
prolonged exposure increased killing to > 90% (Fig. 2).
Alloreactive antibodies can lead to rejection of transplants
through the induction of ADCC or activation of the comple-
ment cascade. Human antibodies specific for the HLA of the
hESC-derived cells or a third party were used to induce cyto-
toxicity by peripheral blood lymphocytes or by rabbit comple-
ment. hESC-PEs were not sensitive to alloreactive antibody-
induced cytotoxicity unless HLA was upregulated by IFNγ
(Fig. 4). In vivo-differentiated hESC-ECs exhibited an in-
creased sensitivity to antibody-induced cellular cytotoxicity
without prior inflammatory HLA upregulation, but not to
complement-dependent cytotoxicity, regardless of IFNγ up-
regulation of HLA (Fig. 4).
Discussion
Insights into the immunogenicity of beta cell-like cells from
sources that are alternatives to human cadaver islets will help
the decision-making process when choosing immune-protective
strategies to test and the most relevant immune monitoring to
perform in clinical translation. hESC-PEs are promising candi-
dates for clinical application [30]. We therefore investigated the
immunological properties of hESC-derived pancreatic cell prep-
arations before and after differentiation to endocrine cells. We
found that hESC-PEsmaintain immune privilegewith lowHLA
expression, although upregulation appears possible in inflamma-
tory conditions which then render the cells vulnerable to adap-
tive immune responses. In vivo differentiation of hESC-PEs into
a preparation with pancreatic endocrine cells also leads to im-
munological differentiation with increasing HLA expression
and sensitivity to adaptive immune responses and also increased
resistance to complement-mediated attack. Recognition and de-
struction by autoreactive PPI-specific T cells verified mature
beta cell immune presentation by hESC-ECs.
Low expression of HLA by hESCs and hESC-derived cells
underlies the hypoimmunogenicity observed in most pub-
lished studies, effectively hiding cells from T cell recognition
and alloreactive antibodies, while differentiation can upregu-
late HLA and increase vulnerability to immunity [17–21]. In
our study, immunogenicity to alloreactive and peptide
(CMV)-specific responses was related to HLA expression.
hESC-PEs expressed very low levels of HLA in a non-
inflamed environment, making them hypoimmunogenic,
while differentiation to hESC-ECs resulted in an increase in
HLA expression and immunogenicity to T cells to levels re-
ported for human islets in the literature [23, 31–34].
Despite the hypoimmunogenicity of hESC-PEs, resistance
was incomplete after prolonged exposure to high numbers of
CTLs. This suggests that hESC-PEs do not employ active
suppression of CTL responses, as has been observed in other
studies [21]. Further, HLA expression could be induced by
mimicking inflammation with IFNγ. While this increased im-
munogenicity to alloreactive T cells and antibodies, the in-
complete immune privilege may help to ensure adequate virus
control in case of infection and prevent destruction by
inflammation-activated NK cells [35].
Increased expression of HLA through inflammation or dif-
ferentiation of hESC to beta cells may make cells vulnerable
to recurrent autoimmunity if cells are transplanted to an HLA-
matched individual with type 1 diabetes. After realising HLA
match through transduction of in vivo-differentiated hESC-
ECs, the insulin-expressing cells could be selectively elimi-
nated by autoreactive CTLs previously isolated from a donor
with type 1 diabetes [23]. Thus, we show hESC-derived beta
cells risk recurrent autoimmunity in an HLA-matched setting.
Further, by proving presentation of the PPI peptide recognised
by the CTL clone, we verify that hESC-ECs have active cel-
lular mechanisms in place to ensure immune surveillance and
that they display genuine insulin production allowing natural
presentation of PPI epitopes in HLA.
In vivo differentiation of hESC-PEs to hESC-ECs in-
creased resistance to complement-mediated attack despite
Diabetologia (2017) 60:126–133 131
increased expression of antigen (HLA) recognised by
alloreactive antibodies. Protection from complement is medi-
ated through complement inhibitory receptors, such as CD46
(MCP), CD55 (DAF) and CD59 (MIP), which are known to
be expressed by human islets [36, 37]. All three receptors were
expressed by the hESC-derived cells but CD55 expression
was low on hESC-PEs, which may explain their vulnerability
to complement-mediated cytotoxicity.
Although we were able to study diverse immune mecha-
nisms relevant for transplantation of alternative beta cells, ex-
trapolation of these results to the clinical transplantation setting
is limited by several factors. First, animal models for in vivo
differentiation of hESC-PEs to hESC-ECs may not completely
reflect the differentiation process in humans. Second, culture
conditions that are required for investigation of explanted
in vivo-differentiated cells may alter the properties of the cells
or the composition of the population. To this end, staining for
beta cells did not show selective reduction of beta cells.
Incomplete dissociation of naturally aggregating hESC-derived
pancreatic endodermal cells and endocrine cells required for
immune assays may contribute to the variation and relatively
large standard error in the cytotoxicity assays (Figs 2, 4).
A head-to-head comparison with primary human islet cells
would be of interest and was considered when setting up this
study. However, it proved to be logistically impossible. hESCs
require 4 months of in vivo differentiation into endocrine cells
and the ex vivo experiments must be started within 24 h after
explantation to assure optimal cell quality. The supply of fresh
human islets for research purposes is highly infrequent and
rare, precluding parallel testing with differentiated hESC-
ECs. This was limited further by the HLA restrictions
enforced by this type of experiment. We therefore looked to
data on beta cell immunogenicity from the literature for the
purpose of comparison [23, 31–34, 36].
The identified immunogenicity of hESC-derived pancreat-
ic endocrine cells highlights the need for an immune suppres-
sive strategy for human transplantation. The vulnerability of
these hESC-derived cells to cellular attack and their resistance
to complement-mediated attack suggests that providing pro-
tection by cell-impermeable macro-encapsulation could be a
successful strategy in clinical implementation. Alternatively,
or additionally, the initial hypoimmunogenicity of the
engrafted pancreatic endoderm may provide a window of op-
portunity in which to induce graft-specific tolerance.
In conclusion, pancreatic endoderm progenitors maintain
hypoimmunogenicity, while differentiation of hESCs to pan-
creatic endocrine cells increases vulnerability to cellular im-
munity. Inflammatory conditions further increase immunoge-
nicity. Yet, maturation of pancreatic endoderm to endocrine
cells enforces resistance to complement-mediated cytotoxici-
ty. This implies that, while simply preventing inflammation
around transplantation of pancreatic endoderm may suffice
initially, the maturing graft may need protection from cellular
immune attack. Therefore, protecting grafts by cell-
impermeable macro-encapsulation could be a successful strat-
egy in clinical implementation. Alternatively, or in addition,
the hypoimmunogenicity of the initially engrafted pancreatic
endoderm may create a window of opportunity in which to
induce graft-specific tolerance.
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